Sun Pharma - Halol Import Alert, Expect Low To Mid Single Digit EPS Impact: Systematix
Potentially, an unexpected high value complex generic launch in the U.S. may offset this adverse impact.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
The U.S. Food and Drugs Administration import alert issued at Sun Pharmaceutical Industries Ltd.’s largest manufacturing facility – Halol – was unexpected, but the potential adverse impact on consolidated earnings will be very much contained owing to product exemptions and scale which Sun Pharma has built in the U.S. through its specialty launches.
Potentially, an unexpected high value complex generic launch in the U.S. may offset this adverse impact. Sezaby is one such potential high value launch which can be material and help Sun Pharma offset this impact.
Sezaby will be manufactured at Baska facility near Halol. About 14 products which are exempted from import alert contribute approximately 50% of sales from Halol to the U.S.
We estimate a higher decline ($90 million) though in FY24E which assumes incremental impact of withdrawal of exemption on certain currently exempted products.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.